3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
92
Polycystic Ovary Syndrome
11
Neoplasm Metastasis
7
Infertility
5
Carcinoma, Ductal, Breast
5
Carcinoma, Lobular
4
Osteoporosis
3
Neoplasms, Hormone-Dependent
3
Neoplasms
3
Breast Neoplasms, Male
3
Advanced Breast Cancer
3
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Carcinoma In Situ
2
Bone Diseases, Metabolic
2
Unilateral Breast Neoplasms
1
Recurrence
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Osteitis Deformans
1
Obesity
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 1
1
Low Grade Serous Ovarian Cancer
1
Infertility, Female
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Hereditary Breast and Ovarian Cancer Syndrome
1
HR+/HER2- Breast Cancer
1
HER2+ Breast Cancer
1
Interventions
ribociclib
1
Tamoxifen
1
Letrozole
1
Goserelin
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Advanced Metastatic Breast Cancer
×
Letrozole
×
Clear all
NCT02278120
2024-03-12
MONALEESA-7
Novartis
Phase 3
Completed
672 enrolled
16 charts
1 FDA